Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3904088 | 0.89 | LMNA (0.45) | MAPTKMT2ACYP1A2POLBHDAC3 | |
| SCHEMBL4231541 | 0.88 | MAPT (0.50) | MAPTKMT2ACYP1A2CYP3A4RECQL | |
| SCHEMBL3904092 | 0.83 | KMT2A (0.40) | MAPTKMT2ACYP1A2CYP3A4RECQL | |
| SCHEMBL10741457 | 0.79 | KCNN4 (0.44) | MAPTKMT2ACYP1A2CYP3A4RECQL | |
| SCHEMBL9874721 | 0.79 | MAPT (0.45) | MAPTKMT2ACYP1A2CYP3A4RECQL | |
| SCHEMBL10950580 | 0.79 | CYP1A2 (0.55) | MAPTKMT2ACYP1A2CYP3A4RECQL | |
| SCHEMBL2462307 | 0.78 | MAPT (0.48) | MAPTKMT2ACYP1A2CYP3A4RECQL | |
| SCHEMBL28250046 | 0.78 | POLB (0.49) | MAPTKMT2ACYP1A2CYP3A4RECQL | |
| Bromide SCHEMBL10946161 | 0.77 | CYP1A2 (0.54) | MAPTKMT2ACYP1A2CYP3A4RECQL | |
| SCHEMBL8380156 | 0.75 | CYP1A2 (0.48) | MAPTKMT2ACYP1A2CYP3A4RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3551182-A1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN | TOPICAL INNOVATIONS B.V. (NL) | 2019-10-16 | — | — | EP | claimed |
| WO-2018106108-A1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN | KEPPEL HESSELING, Jan Marius (NL) | 2018-06-14 | — | — | WO | claimed |
| US-20130005786-A1 | THERAPEUTIC INVENTION | KAPOOR RAJU (GB) | 2013-01-03 | — | — | US | claimed |
| US-20070244074-A1 | Stable parenteral formulation of fosphenytoin sodium | STRIDES ARCOLAB LIMITED (IN) | 2007-10-18 | — | — | US | claimed |
| EP-3551182-B1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN | TOPICAL INNOVATIONS B V (NL) | 2025-03-19 | — | — | EP | disclosed |
| EP-3551166-B1 | TOPICAL PHENYTOIN FOR USE IN THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN | TOPICAL INNOVATIONS B V (NL) | 2024-08-21 | — | — | EP | disclosed |
| US-20240033223-A1 | FOSPHENYTOIN SODIUM SOLID COMPOSITION, LYOPHILIZATION METHOD, AND USE OF FOSPHENYTOIN SODIUM SOLID COMPOSITION | FIDELITY BIOPHARMA CO. | 2024-02-01 | — | — | US | disclosed |
| EP-4257120-A1 | FOSPHENYTOIN SODIUM SOLID COMPOSITION, LYOPHILIZATION METHOD, AND USE OF FOSPHENYTOIN SODIUM SOLID COMPOSITION | Sichuan Credit Pharmaceutical Co., Ltd (CN) | 2023-10-11 | — | — | EP | disclosed |
| CN-114588116-A | Solid composition of fosphenytoin sodium, freeze-drying method and application thereof | 四川科瑞德制药股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-11285099-B2 | Topical phenytoin for use in the treatment of peripheral neuropathic pain | TOPICAL INNOVATIONS B.V. (NL) | 2022-03-29 | — | — | US | disclosed |
| US-11147799-B2 | Topical pharmaceutical composition containing phenytoin and a (co-) analgesic for the treatment of chronic pain | Keppel Hesselink, Jan Marius (NL) | 2021-10-19 | — | — | US | disclosed |
| US-20200276106-A1 | TOPICAL PHENYTOIN FOR USE IN THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN | TOPICAL INNOVATIONS B.V. (NL) | 2020-09-03 | — | — | US | disclosed |
| US-6432923-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | NOVARTIS AG (CH) | 2002-08-13 | — | — | US | disclosed |
| US-6407065-B1 | PREVENT CELL ADHESION; ANTIINFLAMMTORY AGENTS, RESPIRATORY SYSTEM DISORDERS | NOVARTIS AG (CH) | 2002-06-18 | — | — | US | disclosed |
| US-6365619-B1 | CYCLIC OLIGOPEPTIDE VCAM-1 INHIBITOR; (S)-.BETA.-(3-METHOXYPROPYL) ((4-((2-METHYLPHENYLAMINOCARBONYLAMINO)-PHENYL) ACETYL)AMINO)ACETYL-AMINO-3,4-DIMETHOXY-BENZENEPROPANOIC ACID | NOVARTIS AG (CH) | 2002-04-02 | — | — | US | disclosed |
| WO-2001042192-A2 | VLA-4 INTEGRIN ANTAGONISTS | NOVARTIS AG (CH) | 2001-06-14 | — | — | WO | disclosed |
| EP-0726761-B1 | MICROPARTICULAR PHARMACEUTICAL COMPOSITIONS IN MICELLAR FORM | ISOMED INC (US) | 2001-01-10 | — | — | EP | disclosed |
| EP-1049665-A1 | VLA-4 ANTAGONISTS | Novartis AG (Novartis SA) (Novartis Inc.) (CH) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037605-A1 | VLA-4 ANTAGONISTS | NOVARTIS AG (CH) | 1999-07-29 | — | — | WO | disclosed |
| US-5858398-A | MICROPARTICLES CONTAINING ACTIVE AGENT, MIXTURE OF PHOSPHOLIPIDS, MIXTURE OF NONIONIC SURFACTANTS, STEROL SUSPENDED IN FATTY ACID | ISOMED INC. (US) | 1999-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244074-A1 | Stable parenteral formulation of fosphenytoin sodium | TPMT, TTPA, TYMP | MAPT 424/4885KMT2A 1025/4885CYP1A2 458/4885 |
| US-20240033223-A1 | FOSPHENYTOIN SODIUM SOLID COMPOSITION, LYOPHILIZATION METHOD, AND USE OF FOSPHENYTOIN SODIUM SOLID COMPOSITION | FOS, CA3, SORD | MAPT 190/4885KMT2A 2038/4885CYP1A2 908/4885 |
| US-20130005786-A1 | THERAPEUTIC INVENTION | AQP4, PMP22, NHERF1 | MAPT 1803/4885KMT2A 2062/4885CYP1A2 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.